Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)

Phase 2

• Conditions: Gastric Cancer
• Interventions: Drug: Placebo; Drug: Anlotinib

• Registration Number: NCT02461407
• Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Brief Summary

The purpose of this study is to compare the effects and safety of Anlotinib with placebo in patients with Gastric Cancer.

Detailed Description

Not available

Study Timeline

• Study Start: 2015-06
• Study First Submitted: 2015-06-01
• Study First Submitted QC: 2015-06-02
• Study First Posted: 2015-06-03
• Status Verified: 2017-08
• Primary Completion: 2017-12
• Study Completion: 2017-12
• Last Update Submitted: 2017-12-27
• Last Update Posted: 2017-12-29

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 378

Inclusion Criteria

1. Signed and dated informed consent;
2. Pathologically confirmed advanced gastric adenocarcinoma (including Gastroesophageal junction adenocarcinoma) with measurable lesions outside stomach (RECIST 1.1)
3. Advanced stomach cancer patients who have failed to the second line or higher line chemotherapy treatment
4. >=18 years old；ECOG PS：0~1；Estimated life expectancy >3 months
5. Main organs function is normal;

Exclusion Criteria

1. Patients who have been treated with anlotinib previously;
2. Patients who have been treated with other VEGFR-TKI small-molecule drugs previously, such as sunitinib, Sorafenib, famitinib, Apatinib, Regorafenib, ect
3. Patients suffering from other malignancies currently or within 5 years, except for cured cervical carcinoma in situ, non-melanoma skin cancers and superficial bladder cancer [ Ta (non-invasive carcinoma), Tis (carcinoma in situ) and T1 (carcinoma invasion into lamina propria) ]
4. Systemic anti-cancer therapy scheduled 4 weeks prior to assignment or during this study，including cytotoxic therapy，signal transduction inhibitors，immunotherapy(or received mitomycin C within 6 weeks before this study). Extended field radiotherapy(EF-RT) used within 4 weeks prior to assignment or limited field radiotherapy used to assess tumor lesions within 2 weeks prior to assignment;
5. CTCAE(4.0) Grade 1 or higher non-remission toxicity induced by any other previous treatments，excluding alopecia and Grade 2 or lower neurotoxicity induced by oxaliplatin;
6. Patients with a clear tendency of gastrointestinal bleeding;
7. Patients with factors that could affect oral medication (such as dysphagia，chronic diarrhea etc.)
8. Patients with pleural effusion or ascites, causing respiratory syndrome (CTCAE Grade 2 or higher dyspnea [Grade 2 dyspnea refers to Shortness of breath with a small amount of activities, affecting Instrumental activities of daily life])
9. Patients with any severe and/or unable to control diseases;
10. Patients underwent major surgical treatment，open biopsy or significant traumatic injury within 28 days prior to assignment;
11. Patients with any physical signs of bleeding diathesis or medical history, no matter how serious degree they are; Patients with any CTCAE Grade 3 or higher bleeding events occurred within 4 weeks prior to assignment; Patients with non-healing wounds，ulcers or fractures;
12. Patients with arterial or venous thromboembolic events occurred within 6 months, such as cerebrovascular accident (including transient ischemic attack), deep vein thrombosis and pulmonary embolism;
13. Patients with drug abuse history and unable to get rid of or Patients with mental disorders
14. Brain metastases patients with symptoms or symptoms controlled < 2 months;
15. Patients participated in other anticancer drug clinical trials within 4 weeks or Patients participating in other clinical trials now;

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Placebo QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
Anlotinib	Anlotinib	Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent

Primary Outcome Measures

Name	Time	Method
Overall Survival (OS)	From randomization until death (up to 24 months)

Secondary Outcome Measures

Name	Time	Method
Objective Response Rate (ORR)	each 42 days up to intolerance the toxicity or PD (up to 24 months)
Progress free survival (PFS)	each 42 days up to PD or death(up to 24 months)
Disease Control Rate (DCR)	each 42 days up to intolerance the toxicity or PD (up to 24 months)

Trial Locations

Locations (38)

The First Affiliated Hospital, Anhui Medical University; 🇨🇳 Hefei, Anhui, China

Beijing Cancer Hospital; 🇨🇳 Beijing, Beijing, China

The 307th Hospital of Chinese People's Liberation Army; 🇨🇳 Beijing, Beijing, China

Chongqing Daping Hospital; 🇨🇳 Chongqing, Chongqing, China

Union Hospital of Fujian Medical University; 🇨🇳 Fuzhou, Fujian, China

Fujian Cancer Hospital; 🇨🇳 Fuzhou, Fujian, China

Lanzhou General Hospital; 🇨🇳 Lanzhou, Gansu, China

Sun Yat-sen University Cancer Center; 🇨🇳 Guangzhou, Guangdong, China

The People's Hospital of Guangxi Zhuang Autonomous Region; 🇨🇳 Nanning, Guangxi, China

Fourth Hospital of Hebei Medical University Tumor Hospital of Hebei Province; 🇨🇳 Shijiazhuang, Hebei, China

Scroll for more (28 remaining)